Transplant Outcomes in Acute Myeloid Leukemia

Durable remission and improved survival were demonstrated for patients who achieved very low-level measurable residual disease in peripheral blood prior to allogeneic transplantation.

Transplant-eligible adults with acute myeloid leukemia (AML) and higher-risk molecular subtypes typically undergo allogeneic hematopoietic cell transplantation (allo HCT) to deepen response and improve cure rates. To determine the impact of residual peripheral blood leukemic cell DNA on post-transplant outcomes, investigators conducted a multicenter retrospective analysis of patients who underwent allo HCT during first complete remission following induction chemotherapy.

Eligible patients had mutations at the time of AML diagnosis (FLT3, NPM1, IDH1, IDH2, and/or KIT) as well as a remission blood sample obtained within 100 days of the allo HCT. Transplants were performed at least 3 years before the study analysis. DNA analysis for measurable …

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Transplant Outcomes in Acute Myeloid Leukemia

Topics

Reviewing Author